Biofrontera

Biofrontera Net Debt/Equity

The Net Debt to Equity Ratio of Biofrontera (B8FK.DE) as of Nov 21, 2026 is -0.20. In the previous year, Net Debt to Equity Ratio was -0.13 — a change of 50.27% (lower).

Net Debt/Equity

-0.20

YoY

50.27%

Last updated:

Net Debt to Equity Ratio of Biofrontera is 2025 -0.20 . Net Debt to Equity Ratio of Biofrontera was 2024 -0.13 . It decreases by 50.27% lower compared to the previous year.

The Biofrontera Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2018
-0.36 EUR
Jan 1, 2019
1.12 EUR
Jan 1, 2020
0.99 EUR
Jan 1, 2021
-0.06 EUR
Jan 1, 2022
-0.24 EUR
Jan 1, 2023
-0.10 EUR
Jan 1, 2024
-0.13 EUR
Jan 1, 2025
-0.20 EUR
The Biofrontera Net Debt/Equity history
YEARNet Debt/EquityYoY
-0.20+50.27%
-0.13+38.03%
-0.10-59.64%
-0.24+281.55%
-0.06-106.33%
0.99-11.25%
1.12-413.01%
-0.36-238.60%
0.26-132.32%
-0.80-48.07%
-1.54-98.83%
-131.56—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

Net Debt to Equity Ratio of Biofrontera is -0.20 in 2025.

Net Debt to Equity Ratio of Biofrontera changed from -0.13 to -0.20, representing a 50.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio Biofrontera since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's Biofrontera with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Biofrontera

All Key Metrics — Biofrontera